This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcdougall, C. Articles by Fisher, M. Search for Related Content Social Bookmarking                         What's this?

Prevention of diabetes in cardiovascular studies: implications for the aetiology of type 2 diabetes

Miles Fisher

Wards 10 & 11, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0SF, miles.fisher{at}northglasgow.scot.nhs.uk

Recent studies have shown the importance of lifestyle measures in preventing or delaying the development of type 2 diabetes in people with impaired glucose tolerance (IGT). Lifestyle measures appear to be more beneficial than therapy with metformin, or acarbose, and the benefit is most likely to be mediated by reductions in insulin resistance. Several large, multi-centre cardiovascular studies have also been performed where the development of new diabetes has been a secondary end point, and some ACE inhibitors, angiotensin receptor antagonists, and statins also appear to prevent or delay the development of diabetes in at-risk patients. These may act by increasing insulin sensitivity, decreasing inflammatory markers, or by affecting other key components of the metabolic syndrome. This is being tested in ongoing studies in patients with IGT.

Key Words: diabetes • cardiovascular disease • insulin resistance • ACE inhibitors • angiotensin receptor antagonists • statins.

References

• Tuomilehto J., Lindstrom J., Eriksson JG et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
• Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle or metformin. N Engl J Med 2002; 346:393-403.[Abstract/Free Full Text]
• Chiasson J-L., Josse RG, Gomis R. et al. for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
• Dahlof B., Devereux RB, Kjeldsen S. et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Outcomes prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lindholm LH, Ibsen H., Dahlof B. et al. for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson L., Zanchetti A., Carruthers SG et al. for the HOT study group. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shepherd J., Cobbe SM, Ford I. et al. for the West of Scotland Coronary prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-07.[Abstract/Free Full Text]
• Hansson L., Lindholm LH, Niskanen et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Eriksson J., Lindstrom J., Valle T. et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on feasibility of the lifestyle intervention programme. Diabetologia 1999;42:793-801.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yusuf S., Gerstein H., Hoogwerf B. et al. for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.[Abstract/Free Full Text]
• Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2002;359:990-1.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• Sacks FM, Tonkin AM, Shepherd J. et al. for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.[Abstract/Free Full Text]
• Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.[Abstract/Free Full Text]
• Haffner SM Do interventions to reduce coronary heart disease reduce the incidence of Type 2 diabetes? A possible role for inflammatory markers. Circulation 2001;103:346-7.[Free Full Text]
• Freeman DJ, Norrie J., Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.[Abstract/Free Full Text]
• Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ziccardi P., Nappo F., Giugliano G. et al. Reduction in inflammatory cytokine concentrations and improvement in endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-09.[Abstract/Free Full Text]
• Eriksson J., Taimela S., Koivisto VA Exercise and the metabolic syndrome. Diabetologia 1997;40:125-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Krentz AJ, Bailey CJ Pharmacological treatment I In: Krentz AJ, Bailey CJ, Type 2 diabetes in practice. Royal Society of Medicine Press, London, 2001:125-40.
• Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995;44:267-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lithell HO Effects of antihypertensives drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14:203-09.[Abstract]
• Mancini GB, Henry GC, Macaya C. et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65.[Abstract/Free Full Text]
• Carlsson PO, Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998;41:127-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ferrannini E., Seghieri G., Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994;24(suppl 3):S61-9.[Web of Science][Medline] [Order article via Infotrieve]
• Mullen MJ, Wright D., Donald AE et al. 2000. Atorvastatin but not L-arginine improves endothelial dysfunction in type I diabetes mellitus: a double blind study. J Am Coll Cardiol 2000;36:410-16.[Abstract/Free Full Text]
• Evans AJ, Krentz AJ Recent developments and emerging therapies for type 2 diabetes. Drugs in Research and Development 1999;2:275-94.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 5, 384-389 (2002)
DOI: 10.1177/14746514020020050701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcdougall, C. Articles by Fisher, M. Search for Related Content Social Bookmarking                         What's this?